TrialsgrambetaRCTs are beautiful

FINEARTS-HF

2024

Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

In 6,001 patients with heart failure and an ejection fraction ≥ 40 %, finerenone reduced worsening-heart-failure events and cardiovascular death compared with placebo.

Result

Efficacy: Total worsening-HF events + CV deathrate ratio 0.84

Below 1 favours finerenone, above 1 favours placebo.

Also reported: CV death alone not significant; hyperkalaemia ~ 10 %.

Original publication
Subtopic
MRA
Design
Double-blind RCT
Relevance
Important: one of several pillars.
Source
Solomon SD, et al. N Engl J Med. 2024;391(16):1475-1485.doi 10.1056/NEJMoa2407107

Discussion & critique

First non-steroidal MRA win in HFpEF/HFmrEF. Modest, hospitalisation-driven benefit; adds to SGLT2 inhibitors rather than replacing them.

Discussed in podcasts